$MNKD Recent Headlines Skullcandy gains on

New Post Public Reply Private Reply Replies (0) Message Board

Aug 24, 2014 at 10:37 AM

$MNKD Recent Headlines

Skullcandy gains on upgrade,Tesla reverses gains 2:37 p.m. Aug. 12, 2014 - Sue Chang
U.S. small caps lead broad stock-market gains 4:09 p.m. Aug. 11, 2014 - Anora Mahmudova
Kinder Morgan soars, Tesla rallies on upgrade 12:46 p.m. Aug. 11, 2014 - Sue Chang
MannKind shares soar on Sanofi deal; investors ignore earnings report 10:10 a.m. Aug. 11, 2014 - Russ Britt
Super-Moon illusion or buy the dips on this stock market? 7:52 a.m. Aug. 11, 2014 - Barbara Kollmeyer
MannKind shares soar 23% on Sanofi deal over Afrezza 7:04 a.m. Aug. 11, 2014 - Silvia Ascarelli
Sanofi, MannKind to commercialize Afrezza insulin therapy 5:32 a.m. Aug. 11, 2014 - Silvia Ascarelli
Puma Biotech’s blast-off is not a typical short squeeze 12:10 p.m. July 23, 2014 - Tomi Kilgore
S&P 500 posts strongest 2nd quarter since 2009: Stock market live blog recap 3:33 p.m. June 30, 2014 - blogs.marketwatch.com
MannKind, GoPro rise; Yahoo gains on upgrade 12:02 p.m. June 30, 2014 - Sue Chang
MannKind shares up 23.1% in premarket trade 7:19 a.m. June 30, 2014 - Ciara Linnane
Six more bull months ahead, and GoPro keeps on going 6:28 a.m. June 30, 2014 - Sara Sjolin
MannKind wins approval for its inhaled insulin — and its stock drops? 4:30 p.m. June 27, 2014 - Russ Britt
DuPont falls on outlook; Michaels debuts 4:08 p.m. June 27, 2014 - Sue Chang
3 overlooked stocks loved by top-ranked advisers 3:09 p.m. April 25, 2014 - Mark Hulbert
Tesla, Facebook seesaw; Questcor surges on deal 3:54 p.m. April 7, 2014 - Sue Chang
MannKind drops after FDA says its review on drug will last until July 1:46 p.m. April 7, 2014 - Russ Britt
Stock futures drop as earnings season looms 9:20 a.m. April 7, 2014 - Sara Sjolin
MannKind drops 12% after FDA review extension 7:15 a.m. April 7, 2014 - Ben Eisen
MannKind drops 16% after FDA review extension 7:01 a.m. April 7, 2014 - Ben Eisen

How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug 12:43 p.m. Aug. 20, 2014 - GuruFocus.com
MannKind Corporation: Back To The Fundamentals 11:50 a.m. Aug. 20, 2014 - Seeking Alpha
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind 2:31 p.m. Aug. 19, 2014 - GuruFocus.com
Hottest Healthcare Stocks Now – CLDX KND PDLI MNKD 7:30 a.m. Aug. 19, 2014 - InvestorPlace.com
MannKind Corp. And The Folly Of Cult Biotech Stocks 8:51 a.m. Aug. 18, 2014 - Seeking Alpha
Hottest Healthcare Stocks Now – LCI HMSY CBPO MNKD 8:45 a.m. Aug. 18, 2014 - InvestorPlace.com
5 Stocks With Awful Sales Growth — HTS MITT UEC MNKD CTEL 4:00 a.m. Aug. 18, 2014 - InvestorPlace.com
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza 8:59 a.m. Aug. 15, 2014 - GuruFocus.com
10 Known Unknowns That Matter For MannKind Investors 4:45 p.m. Aug. 14, 2014 - Seeking Alpha
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune 3:38 p.m. Aug. 14, 2014 - GuruFocus.com
10 Cheap Stocks to Buy Now Under $10 10:20 a.m. Aug. 14, 2014 - InvestorPlace.com
Properly Treating Costs: Re-Evaluating The MannKind And Sanofi Partnership 4:53 p.m. Aug. 13, 2014 - Seeking Alpha
Blame MannKind's Fall on its Bloated Balance Sheet 12:04 p.m. Aug. 13, 2014 - TheStreet.com
Update: MannKind Q2 Earnings - Stock Sent To The Woodshed 10:14 a.m. Aug. 13, 2014 - Seeking Alpha
A Deeper Look At MannKind - Sanofi Deal And Valuation 10:02 a.m. Aug. 13, 2014 - Seeking Alpha
What the Market is Telling MannKind 9:00 a.m. Aug. 13, 2014 - 247WallSt.com
MannKind Corporation (MNKD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Aug. 13, 2014 - Zacks.com
Cramer's Mad Money - These 2 Sectors Have A Huge Void (8/12/14) 6:09 a.m. Aug. 13, 2014 - Seeking Alpha
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog 11:05 a.m. Aug. 12, 2014 - Zacks.com
MannKind: Looking Beyond The Short-Term Disappointment 10:00 a.m. Aug. 12, 2014 - Seeking Alpha

Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna 8:30 a.m. Aug. 14, 2014 - PR Newswire - PRF
Critical Alerts For MannKind, Kinder Morgan, Kohls, Maxim Integrated Products and United Technologies. Released By InvestorsObserver 9:31 a.m. Aug. 12, 2014 - PR Newswire - PRF
MannKind Corporation Reports 2014 Second Quarter Financial Results 9:01 a.m. Aug. 11, 2014 - GlobeNewswire
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin 7:00 a.m. Aug. 11, 2014 - PR Newswire - PRF
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin 1:13 a.m. Aug. 11, 2014 - GlobeNewswire
MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014 5:00 p.m. Aug. 5, 2014 - GlobeNewswire
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 9:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver 9:31 a.m. July 21, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
MannKind Corp Analyst Report; Afrezza is Approved and Future Developments by BrokerBank Securities, Inc. 11:15 a.m. July 3, 2014 - PR Newswire - PRF
Critical Alerts For MannKind, AOL, Plug Power, Ctrip.com, and 58.com Released By InvestorsObserver 9:31 a.m. July 1, 2014 - PR Newswire - PRF
MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes 5:07 p.m. June 27, 2014 - GlobeNewswire
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva 5:20 a.m. June 26, 2014 - PR Newswire - PRF
Critical Alerts For Netflix, MannKind, Dish Network, Illumina, and Anheuser-Busch InBev Technology Released By InvestorsObserver 9:31 a.m. June 6, 2014 - PR Newswire - PRF
MannKind to Present at Upcoming Conferences 9:01 a.m. May 27, 2014 - GlobeNewswire
Reveal Insider Trading for Facebook, MannKind, QUALCOMM, American Realty Capital Properties, salesforce.com, and Symantec 8:55 a.m. May 22, 2014 - PR Newswire - PRF
Technical Data on Top Gainers -- Research on MannKind, Intermolecular, FireEye, and Yingli Green Energy Holding 9:10 a.m. May 20, 2014 - PR Newswire - PRF
Earnings Release Results, and Leadership Appointments - Analyst Notes on Halozyme, MannKind, Arrowhead, Idera and BioCryst 7:00 a.m. May 16, 2014 - PR Newswire - PRF
Critical Alerts For Citigroup, Linn Energy, MannKind, Canadian Solar, and Qualcomm Released By InvestorsObserver 9:31 a.m. May 15, 2014 - PR Newswire - PRF
MannKind Corporation Pending FDA Approval Inspires Analyst Report by BrokerBank Securities, Inc. 8:00 a.m. May 14, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicken Salad Chick's Utah Expansion: The Next Course

A New Serving in Spanish Fork Chicken Salad Chick is taking another bite out of the Utah market with the opening of its second location in Spanish Fork. On deck for a November 17 debut, this fast-casual chain is serving up not just chicken salad, but a hefty dose of Southern hospitality and promotional giveaways to boot. The big hook? Be among the first 100 patrons and...

Good Springs Earns Spot on Inc.'s 2026 Founder List

There's a badge of honor in the investment world that's not about the dollars and cents pouring in—it's about having founders trust you to take care of their business babies. Good Springs Capital just snagged one by being named to Inc.'s 2026 Founder-Friendly Investors list. Now, if you're thinking this is just some fancy accolade, let's chew over the real nuggets here....

Bird-X Welcomes Doolittle to Elevate Sales Strategy

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Hagerty Amplifies Profit Forecast Amid Premium Gains

An Unyielding Growth Trajectory Hagerty, Inc. just unveiled its behemoth third quarter results for 2026 and they're nothing if not eye-popping. With a whopping 18% increase in written premium year-over-year to a towering $1,099 million, there's no mistaking Hagerty’s robust growth trajectory. And that's just one piece of the puzzle—earned premiums rocketed up by 42%...

Wet Noses Innovates Human-Grade Pet Food at PLMA 2026

Pet Food Revolution? Wet Noses Takes the PLMA Stage Okay, listen up, pet lovers and industry folks alike—seems like Wet Noses, that Washington-based veteran in the dog treat game, is shaking up the pet food world. After cruising through the pet aisle for almost three decades, they're making a splash at the PLMA 2026. Why should we care? Well, they’re pushing this...

Novartis Pulls the Plug on BioArctic Agreement

Novartis Drops BioArctic Like a Hot Potato Well, folks, it looks like Novartis has decided to pack up its bags and hightail it out of its collaboration with BioArctic AB. This ain't just any small piece of news—it's got ramifications that have folks in the biotech and healthcare sector scratching their heads and, probably, feeling a mixture of apprehension and...

Truecaller's Strategic Shift: Recovery and Growth in 2026

Grappling with Numbers: Truecaller's Q3 2026 Results A glance at Truecaller's latest report tells us they're banking on a strategic recovery.AOver their recent interim report covering January to September 2026, they disclose a modest 1% decrease in net sales reaching SEK 464 million. Now, if you scoop away the currency fluctuations, net sales climb by a soft 3% from Q2....

Illumina's Role in Singapore's Precision Medicine Leap

Singapore's Bold Step into Precision Medicine When it comes to revolutionizing healthcare, Singapore isn't content to sit on the sidelines. They've just thrown a serious hat into the ring with the SG-INSIGHT study, a cornerstone of their National Precision Medicine programme. And Illumina, Inc. (NASDAQ:ILMN) is right there in it, gearing up to sequence the genomes of...

Elron Ventures Revamps Leadership to Boost Tech Focus

Shaking Up the Leadership Roster The folks over at Elron Ventures are making some big moves, shifting the chess pieces on their leadership board in a bid to bolster their investment and M&A strategy. They're bringing in fresh blood and seasoned vets alike to navigate the rocky waters of Defense Tech, Deep Tech, Cybersecurity, and AI. You reckon they're onto something,...

Restorative Getaways Aid Grieving Families, Offers Relief

Finding Solace in Change: The Power of Stepping Away Grieving a lost child. It’s a trip to hell and back, and for many families, the journey feels endless. The press of everyday life—bills, jobs, commutes—offers no mercy. At times, stepping out of the blur might be the prime move toward healing, and that's where restorative getaways step in. Escaping the Everyday...